-
公开(公告)号:US20050026292A1
公开(公告)日:2005-02-03
申请号:US10861302
申请日:2004-06-04
IPC分类号: A01K67/027 , C07K14/47 , C12N5/10 , C12N15/09 , C12N15/85 , C12Q1/02 , G01N33/15 , G01N33/50 , C12N1/20 , C12N15/74
CPC分类号: C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2217/20 , A01K2227/105 , A01K2267/03 , C07K14/47 , C12N2517/02 , C12N2800/30
摘要: Vector constructs and methods for producing non-human transgenic animals comprising within their genome a conditional targeted mutation within the glyt1 gene are provided. These animals can be utilized as a tool for assessing GLYT1 function as well as a model for studying the effects of enhancing synaptic NMDA receptor function. In addition, these animals can be utilized for studying the susceptibility to compounds inducing psychotic behavior.
摘要翻译: 提供用于产生非人转基因动物的载体构建体和方法,其在其基因组内包含glyt1基因内的条件靶向突变。 这些动物可用作评估GLYT1功能的工具,以及研究增强突触NMDA受体功能的作用的模型。 此外,这些动物可用于研究诱导精神病性行为的化合物的易感性。
-
公开(公告)号:US20050210540A1
公开(公告)日:2005-09-22
申请号:US11080962
申请日:2005-03-15
IPC分类号: A01K67/027 , C07K14/47 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/63 , C12N15/85 , C12Q1/00 , C12Q1/02 , G01N33/15 , G01N33/50
CPC分类号: C07K14/47 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0356 , C12N15/8509 , C12N2830/008
摘要: The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the methods of producing same. The invention also relates to the use of these animals as a model for analyzing the effects of depressing synaptic NMDA receptor function and studying the ability of compounds to reduce symptoms of psychotic behavior.
摘要翻译: 本发明提供用于产生转基因非人动物的遗传构建体和方法,其在其基因组中包含编码GLYT1的转基因DNA。 这些转基因动物可以进一步用于产生产生更活性的GLYT1的转基因动物。 还提供了产生更多GLYT1蛋白质的转基因动物以及其生产方法。 本发明还涉及这些动物作为分析抑制突触NMDA受体功能的作用并研究化合物降低精神病性症状的能力的模型。
-
公开(公告)号:US20060070136A1
公开(公告)日:2006-03-30
申请号:US11274814
申请日:2005-11-15
IPC分类号: A01K67/027 , C12N15/63
CPC分类号: C07K14/47 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0356 , C12N15/8509 , C12N2830/008
摘要: The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the methods of producing same. The invention also relates to the use of these animals as a model for analyzing the effects of depressing synaptic NMDA receptor function and studying the ability of compounds to reduce symptoms of psychotic behavior.
摘要翻译: 本发明提供用于产生转基因非人动物的遗传构建体和方法,其在其基因组中包含编码GLYT1的转基因DNA。 这些转基因动物可以进一步用于产生产生更活性的GLYT1的转基因动物。 还提供了产生更多GLYT1蛋白质的转基因动物以及其生产方法。 本发明还涉及这些动物作为分析抑制突触NMDA受体功能的作用并研究化合物降低精神病性症状的能力的模型。
-
公开(公告)号:US20050070539A1
公开(公告)日:2005-03-31
申请号:US10933103
申请日:2004-09-02
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Nettekoven , Roger Norcross , Emmanuel Pinard , Henri Stadler
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Nettekoven , Roger Norcross , Emmanuel Pinard , Henri Stadler
IPC分类号: A61K31/495 , A61K31/496 , A61P25/28 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D295/192 , C07D307/14 , C07D309/14 , C07D43/02 , A61K31/501 , A61K31/506 , A61K31/53
CPC分类号: C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 式的化合物,其中取代基如治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病(如注意力缺陷障碍或阿尔茨海默病)的治疗方法所述。
-
公开(公告)号:US07176316B2
公开(公告)日:2007-02-13
申请号:US10778560
申请日:2004-02-13
IPC分类号: C07D211/56
CPC分类号: C07D413/12 , C07D211/58 , C07D401/08 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/14
摘要: The present invention relates to compounds of the general formula wherein X and Y are each independently selected from —CH2— or —O—, with the proviso that X and Y are not simultaneously —O—; A is —S(O)2— or —C(O)—; and R1, R2, R3, and R4 are as defined in the specification. The compounds are GlyT-1 inhibitors and are useful for the treatment of psychoses, pain, dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 本发明涉及通式的化合物,其中X和Y各自独立地选自-CH 2 - 或-O-,条件是X和Y不同时为-O-; A是-S(O)2 - 或-C(O) - ; R 1,R 2,R 3,R 4和R 4如说明书中所定义。 化合物是GlyT-1抑制剂,可用于治疗精神病,疼痛,记忆功能障碍,学习障碍,精神分裂症,痴呆等认知过程受损的其他疾病,如注意力缺陷障碍或阿尔茨海默病。
-
公开(公告)号:US20050059668A1
公开(公告)日:2005-03-17
申请号:US10933072
申请日:2004-09-01
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Nettekoven , Roger Norcross , Emmanuel Pinard , Henri Stalder
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Nettekoven , Roger Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号: A61K31/495 , A61K31/496 , A61P25/28 , C07D213/56 , C07D213/69 , C07D213/74 , C07D233/54 , C07D239/26 , C07D239/42 , C07D241/12 , C07D251/42 , C07D251/48 , C07D257/04 , C07D263/32 , C07D277/30 , C07D295/16 , C07D295/185 , C07D309/04 , C07D309/20 , C07D333/24 , C07D409/12 , C07D43/02
CPC分类号: C07D295/16 , A61K31/495 , A61K31/496 , C07D213/56 , C07D213/69 , C07D213/74 , C07D233/64 , C07D239/26 , C07D239/42 , C07D241/12 , C07D251/42 , C07D251/48 , C07D257/04 , C07D263/32 , C07D277/30 , C07D295/185 , C07D309/04 , C07D309/20 , C07D333/24 , C07D409/12
摘要: The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 本发明涉及下式的化合物,其中取代基如说明书中所定义,及其药学上可接受的酸加成盐。 本发明还涉及用于治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和认知过程受损的其它疾病如注意力缺陷障碍或阿尔茨海默病的方法。
-
公开(公告)号:US07595314B2
公开(公告)日:2009-09-29
申请号:US12177386
申请日:2008-07-22
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/55 , C07D413/12
CPC分类号: C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 式的化合物,其中取代基如治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病(如注意力缺陷障碍或阿尔茨海默氏病)的描述中所述。
-
公开(公告)号:US20090192136A1
公开(公告)日:2009-07-30
申请号:US12177386
申请日:2008-07-22
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号: A61K31/496 , C07D413/10 , C07D241/04 , A61K31/55 , A61K31/5377 , A61P25/00 , A61K31/495 , C07D405/12
CPC分类号: C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 式的化合物,其中取代基如治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病(如注意力缺陷障碍或阿尔茨海默病)的治疗方法所述。
-
公开(公告)号:US07462617B2
公开(公告)日:2008-12-09
申请号:US10933072
申请日:2004-09-01
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号: A61K31/53 , A61K31/496 , C07D295/192 , C07D409/12 , C07D251/22 , C07D251/24 , A61K31/495
CPC分类号: C07D295/16 , A61K31/495 , A61K31/496 , C07D213/56 , C07D213/69 , C07D213/74 , C07D233/64 , C07D239/26 , C07D239/42 , C07D241/12 , C07D251/42 , C07D251/48 , C07D257/04 , C07D263/32 , C07D277/30 , C07D295/185 , C07D309/04 , C07D309/20 , C07D333/24 , C07D409/12
摘要: The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other d 1iseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 本发明涉及下式的化合物,其中取代基如说明书中所定义,及其药学上可接受的酸加成盐。 本发明还涉及用于治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病的方法,例如注意力缺陷障碍或阿尔茨海默病。
-
公开(公告)号:US07427612B2
公开(公告)日:2008-09-23
申请号:US10933103
申请日:2004-09-02
申请人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人: Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号: A61K31/55 , A61K31/5377 , A61K31/496 , C07D295/192
CPC分类号: C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要: A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译: 式的化合物,其中取代基如治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病(如注意力缺陷障碍或阿尔茨海默氏病)的描述中所述。
-
-
-
-
-
-
-
-
-